Revusiran
- Generic Name
- Revusiran
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1438322-82-7
- Unique Ingredient Identifier
- ZE6EHM8Z3A
- Background
Revusiran is under investigation in clinical trial NCT02319005 (ENDEAVOUR: Phase 3 Multicenter Study of Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)).
- Associated Conditions
- -
- Associated Therapies
- -
The Study of an Investigational Drug, Revusiran (ALN-TTRSC), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Whose Disease Has Continued to Worsen Following Liver Transplant
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-11-04
- Last Posted Date
- 2019-03-28
- Lead Sponsor
- Alnylam Pharmaceuticals
- Target Recruit Count
- 12
- Registration Number
- NCT02595983
- Locations
- 🇬🇧
Clinical Trial SIte, London, United Kingdom
🇸🇪Clinical Trial Site, Umea, Sweden
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath